http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103373997-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb25c233d984147b603aa2495a7f6daf
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14
filingDate 2012-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2affbb0bdab6c524392e45e60a254f9e
publicationDate 2013-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103373997-A
titleOfInvention Pyridonaphthyridine HDAC and mTOR Inhibitors Containing a Zinc-binding Group
abstract The invention belongs to the technical field of medicine, and specifically relates to pyridonaphthyridine derivatives represented by general formula (I) as HDAC and mTOR inhibitors, pharmaceutically acceptable salts thereof, and isomers thereof: wherein A, X , Y, W, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in the description; the present invention also relates to the preparation methods of these compounds, and the pharmaceutical preparations containing these compounds And pharmaceutical compositions, and the application of these compounds in the preparation of medicines for treating and/or preventing diseases related to HDAC and MTOR activity.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014518887-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9475812-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10266487-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10988441-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2719697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753408-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10508077-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10988472-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9745253-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2719697-A4
priorityDate 2012-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009125809-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408841519
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID147655780

Total number of triples: 28.